← Back to blog
7 min read News

Six Teams Compete for $5M Proving Quantum Can Solve Real Healthcare Problems

Wellcome Leap's Q4Bio competition shows hybrid quantum-classical systems tackling cancer diagnostics and drug discovery on today's NISQ hardware.

newshealthcareuse-casesxanadufunding

The quantum computing field faces a critical question: can today’s noisy, error-prone machines do anything useful, or must we wait years for fault-tolerant systems? Six research teams are about to provide an answer.

Wellcome Leap’s Quantum for Bio (Q4Bio) competition, launching March 25 in Marina del Rey, California, offers $5 million to anyone who can demonstrate a quantum algorithm solving a real healthcare problem on 100+ qubits. After 30 months of development, the finalists have converged on a surprising solution: hybrid quantum-classical systems that outsource most computation to classical processors while using quantum hardware only where it provides genuine advantage.

The Hybrid Quantum-Classical Breakthrough

The competition criteria are strict. To win the $5 million grand prize, teams must:

  • Run on 100+ qubit quantum hardware
  • Solve a real healthcare problem that classical computers cannot
  • Meet rigorous performance benchmarks
  • Demonstrate measurable clinical value

A separate $2 million prize goes to teams meeting these criteria on 50+ qubits.

What makes this challenging is the state of current quantum hardware. Today’s machines are noisy, error-prone, and far from the large-scale systems needed for textbook quantum algorithms. But the six finalists found a way forward by creating automated pipelines that determine which parts of a problem need quantum processing and which can remain classical.

“You can think about it as a platform for solving difficult problems in computational genomics,” says Sergii Strelchuk of Oxford University, whose team uses quantum computers to map genetic diversity among humans and pathogens on complex graph-based structures. “You can do all this before you start spending money on computing.”

Real Clinical Applications on NISQ Hardware

The applications are concrete and clinically relevant:

Cancer drug simulation: Helsinki-based Algorithmiq used IBM’s superconducting quantum computer to simulate a photosensitive cancer drug already in Phase II clinical trials for bladder cancer. “The idea is you take the drug, and it’s everywhere in your body, but it’s doing nothing, just sitting there, until there’s light on it of a certain wavelength,” explains Guillermo García-Pérez, Algorithmiq’s chief scientific officer. The quantum simulation allows the drug to be redesigned for other cancer types—something classical methods cannot handle.

Cancer origin detection: Infleqtion’s neutral-atom quantum computer mines the Cancer Genome Atlas to identify patterns that reveal where a patient’s metastasized cancer originated. “It’s very important to know where it came from because that can inform the best treatment,” says quantum software engineer Teague Tomesh. The quantum processor finds correlations in massive datasets that overwhelm classical solvers, then hands the reduced problem back to classical computers.

Muscular dystrophy drug discovery: A Nottingham-based team partnered with QuEra to quantum-compute how drug candidates bind to proteins causing myotonic dystrophy, the most common adult-onset muscular dystrophy. Team member David Brook helped identify the gene behind this condition in 1992; over 30 years later, quantum computing is helping design treatments.

ATP molecule simulation: Stanford’s Grant Rotskoff is investigating the quantum properties of ATP, the molecule that powers biological cells. “We’re very firmly within the criteria for the $2 million prize,” Rotskoff says. The grand prize? “This is really at the very edge of doable.”

The Honest Assessment

Shihan Sajeed, Q4Bio’s program director, maintains measured expectations. “It is very difficult to achieve something with a noisy quantum computer that a classical machine can’t do,” he says. He believes the error-prone quantum machines may not deliver on all grand prize criteria.

But the progress surprised him. “When we started the program, people didn’t know about any use cases where quantum can definitely impact biology. We now know the fields where quantum can matter.”

The hybrid quantum-classical developments are “transformational,” Sajeed notes. Even if no one wins the grand prize, the algorithms developed will be useful on future quantum computers. “It just means the machine you need doesn’t exist yet.”

Winners will be announced mid-April.

What This Means for Quantum Computing

The Q4Bio competition represents a shift in quantum computing strategy. Rather than waiting for fault-tolerant systems in 2030+, researchers are extracting value from today’s NISQ (Noisy Intermediate-Scale Quantum) hardware by:

  1. Automated hybrid pipelines: Algorithms that determine which parts need quantum processing
  2. Classical preprocessing: Using classical methods to reduce problem size before quantum processing
  3. Error mitigation: Software techniques that improve results despite hardware noise
  4. Focused quantum advantage: Using quantum only where it provides genuine speedup

This approach may not deliver the exponential speedups of textbook quantum algorithms, but it provides measurable value today—and that’s what enterprises need to justify investment.

Meanwhile: Xanadu Becomes First Public Photonic Quantum Company

In other major news this week, Xanadu Quantum Technologies completed its SPAC merger with Crane Harbor Acquisition Corp., scheduled to begin trading on Nasdaq and the Toronto Stock Exchange on March 27, 2026, under ticker symbol “XNDU.”

This makes Xanadu the first publicly listed photonic quantum technology company—a significant milestone for an approach that has historically received less attention than superconducting and trapped-ion systems.

The funding: Xanadu expects $302 million in gross proceeds from the merger, consisting of Crane Harbor’s trust account funds and a committed private placement (PIPE). Separately, the company is negotiating up to CAD $390 million from the governments of Canada and Ontario through Project OPTIMISM.

Why photonics matters: Xanadu’s light-based approach operates at room temperature, bypassing the cryogenic infrastructure required by superconducting qubits. The company’s modular, networked architecture aims to scale more easily than competing approaches.

Beyond hardware, Xanadu maintains PennyLane, an open-source quantum programming library widely used for quantum machine learning across multiple hardware platforms. This software ecosystem provides a hedge if photonic hardware faces unexpected challenges—similar to how Nvidia’s CUDA became valuable independent of any single GPU architecture.

Investor perspective: Going public provides capital for hardware scaling and ecosystem development. Founded in 2016 by CEO Christian Weedbrook, Xanadu now has the runway to prove whether photonics can deliver on its theoretical advantages: room-temperature operation, natural networking capabilities, and integration with existing telecommunications infrastructure.

Two Paths Forward

This week’s developments illustrate two parallel paths in quantum computing:

  1. Extract value from current NISQ hardware (Q4Bio approach): Hybrid quantum-classical systems solving specific problems today
  2. Build toward fault-tolerant systems (Xanadu IPO): Invest in hardware platforms expected to scale in the 2030s

Both are necessary. The Q4Bio competition shows quantum can deliver value sooner than many expected—if we accept hybrid solutions rather than waiting for pure quantum advantage. Xanadu’s public listing provides funding for the long-term hardware development that will eventually enable those pure quantum algorithms.

For enterprises watching this space: the Q4Bio results (mid-April) will reveal which healthcare applications justify quantum investment today. The Xanadu IPO will show whether public markets believe in photonic quantum computing’s long-term potential.

Either way, we’re learning what quantum computers can actually do—not just what they might do someday.

Sources & Further Reading

Primary sources:

Context: